What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The pivotal phase 3 trials (COMET-2 and COMET-3) demonstrated significant improvements in tear production compared to vehicle control, with responder proportions of 42.6% and 53.2% respectively. However, the absence of active comparator data against standard of care (SOC) limits the ability to claim superiority over existing treatments, resulting in a rating of B++ for comparable efficacy.
Does the economic case hold at the expected price? — Cost effectiveness
No cost-utility analysis or ICER data were available in the reviewed sources, and the absence of economic modeling or budget impact assessments leads to a conclusion of non-cost-effectiveness.
Is there quality-of-life evidence payers weigh? — Quality of life
While the trials utilized symptom scales like SANDE, there were no generic utility instruments (e.g., EQ-5D) reported, and the evidence for HRQoL improvements is limited and inconsistent. The lack of caregiver impact data further supports a rating of B+.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The most common adverse effect reported was instillation site pain (50%), primarily mild and transient. Serious adverse events were low, with a discontinuation rate due to adverse effects of only 1.6%. This favorable safety profile supports a rating of A+.
Was the drug compared against what payers expect? — Comparator Selection
The pivotal trials used vehicle control rather than active comparators, which is common in dry eye disease studies but limits the ability to assess relative efficacy against SOC. This results in a rating of B+ due to the lack of active comparator data.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials enrolled a diverse population of 931 patients, with a mean age of 61 and a majority being female. This demographic representation supports a rating of A, although subgroup analyses for efficacy were not reported.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Acoltremon is expected to be self-administered in an outpatient setting with no significant changes required to existing care pathways. This ease of integration supports a rating of A.
Are the wider system costs understood? — Resource Use and Cost Implications
No data on direct medical resource use, implementation costs, or avoided events were found in the reviewed sources, leading to a rating of C due to the lack of evidence on resource implications.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The pivotal trials were well-designed, randomized, and double-masked, but the inconsistency in symptom outcomes across trials raises concerns about the robustness of the evidence. Thus, a rating of B++ is appropriate.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the duration of the treatment effect and the lack of economic sensitivity analyses. This leads to a rating of B+ due to the high uncertainty surrounding broader impacts.
